Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;16(9):1292-8.
doi: 10.1634/theoncologist.2011-0043. Epub 2011 Aug 22.

Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience

Hazem El-Osta  1 , David Hong, Jennifer Wheler, Siqing Fu, Aung Naing, Gerald Falchook, Marshall Hicks, Sijin Wen, Apostolia M Tsimberidou, Razelle Kurzrock
Affiliations

Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience

Hazem El-Osta et al. Oncologist. 2011.

Abstract

Background: Research biopsies are crucial for exploring the impact of novel agents on putative targets. The current study assesses the safety and success rate associated with performing such biopsies.

Methods: We reviewed the medical records of 155 consecutive patients who had one or more research biopsies as part of a phase I trial from September 2004 to October 2009.

Results: Of 281 research biopsies performed, 118 were paired before and after treatment biopsies (total = 236 biopsies). The most common sites of biopsy were superficial lymph node (19.9%), followed by liver (16.4%), and then soft tissue (15.7%). Ultrasound-guided biopsies were the most frequent type (53.7%). Among 142 patients who consented for mandatory biopsy, 86.6% had the biopsy performed, compared with 4.4% of 911 patients offered a biopsy on an optional basis (p < .0001). Biopsy was obtained most frequently on industry-sponsored trials; lack of funding on nonindustry trials was the most common reason that biopsies were not obtained. Of 281 single biopsies, only 4 (1.4%) had complications: pneumothorax requiring chest tube placement (n = 2), infection requiring admission (n = 1), and arrhythmia with hypotension (n = 1). All but one biopsy was successful in obtaining tissue. No deaths were attributable to biopsy.

Conclusions: Our experience demonstrates that research biopsies in early phase clinical trials are safe (1.4% risk of serious complications), and a higher percentage of patients underwent mandatory biopsies (86.6%) compared with that of the patients with optional biopsies (4.4%).

PubMed Disclaimer

Conflict of interest statement

Disclosures: Hazem El-Osta: None; David Hong: None; Jennifer Wheler: None; Siqing Fu: None; Aung Naing: Research funding/contracted research: National Institutes of Health; Gerald Falchook: None; Marshall Hicks: None; Sijin Wen: None; Apostolia M. Tsimberidou: None; Razelle Kurzrock: None.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005;352:895–904. - PubMed
    1. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation:theoretical considerations and practical challenges. J Clin Oncol. 2009;27:4027–4034. - PMC - PubMed
    1. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101:708–720. - PMC - PubMed
    1. Peppercorn J, Shapira I, Collyar D, et al. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol. 2010;28:2635–2640. - PMC - PubMed
    1. Dowlati A, Haaga J, Remick SC, et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res. 2001;7:2971–2976. - PubMed

Publication types